PPM Oost, Zeeuws invest $5.2m in Mimetas

Mimetas will use the fresh capital to further develop its 3D disease- and tissue-modelling technology. Specifically, the company will scale up production of its OrganoPlate product.

Earlier this year, the company was awarded $1.6m in funding in a "kidney-on-a-chip" project with GlaxoSmithKline, Pfizer and Roche.

Company
Founded in 2011 as a University of Leiden spinout, Mimetas is headquartered in Leiden with an additional office in Rockville, Maryland, in the US.

The company has developed a microfluidic platform that allows for the testing of drugs on miniaturised organ models, rather than on laboratory animals.

Mimetas's OrganoPlate is designed to support 3D cell culture to mimic aspects of human organs and tissues. The company can develop custom disease and toxicology tissue models.

People
CTO Paul Vulto and chief business officer Jos Joore founded Mimetas. Marius Prins is the CEO of PPM Oost, while Johan Sebregts is a managing director at Zeeuws.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Expansion
• Healthcare
• Netherlands
• PPM Oost